2026 oncology meetings
SITC, ESMO, ASCO, AACR and ASH 2026. 285 abstracts found by web research and verified against a source page so far, plus each meeting's journal supplement searched live through Crossref where it is indexed. Titles and metadata only.
SITC Annual Meeting 2026
4–8 Nov 2026, Phoenix
18
verified abstracts in 1 area
ESMO Congress 2026
23–27 Oct 2026, Madrid
146
verified abstracts in 8 areas
ASCO Annual Meeting 2026
29 May – 2 Jun 2026, Chicago
13
verified abstracts in 1 area
AACR Annual Meeting 2026
17–22 Apr 2026, San Diego
10
verified abstracts in 1 area
ASH Annual Meeting 2026
12–15 Dec 2026, New Orleans
98
verified abstracts in 4 areas
Verified abstracts per 2026 meeting, split by how each row was checked. The rest match the text Parallel saved from a page that blocks automated access, mostly ESMO's congress platform.
Rows that failed every check were dropped and are not counted. Source: data/meetings in the project repository, each row linked to its source page.
SITC Annual Meeting 2026
4–8 Nov 2026, Phoenix · Journal for ImmunoTherapy of Cancer 14 (Suppl 2 and 3), open access
1,109 regular and 19 late-breaking abstracts are in Crossref as open-access JITC supplement records (CC BY-NC); the supplement may still be filling in.
Late-breaking, across tumour types
18 verified · pulled 2026-11-11- 488Poster
- 603PosterMulti-omics analyses reveal intratumoral and systemic immune activation to aglatimagene besadenovec+valacyclovir related to improved survival in patients with progressive NSCLC despite ICI treatmentaglatimagene besadenovecvalacyclovirVerified on source pageir.candeltx.com
- 1174PosterPeripheral immune correlates of denileukin diftitox-cxdl plus pembrolizumab in heavily pretreated recurrent or advanced gynecologic malignanciesRobert Edwardsdenileukin diftitox-cxdlpembrolizumabVerified on source pagesitcancer.org
- 1176Poster
- 1179Poster
- 1180PosterInterim safety and efficacy results of Victoria-01: A phase 1 study to evaluate the safety and preliminary efficacy of SOT201 in patients with advanced/metastatic solid tumorsAung NaingVictoria-01SOT201Verified on source pagesitcancer.org
- 1181PosterRoginolisib plus dostarlimab with or without docetaxel reverts immune suppression and shows clinical activity in immunotherapy-resistant non-small cell lung cancer (NSCLC)Reinier Wener (presented by Michael Emig)PULMO-01roginolisibdostarlimabdocetaxelVerified on a second sourcesitcancer.org
- 1182PosterSafety and preliminary antitumor activity of the oral ENPP1 inhibitor, vizenpistat, combined with botensilimab and balstilimab in refractory metastatic microsatellite stable colorectal cancerAlexis WestonvizenpistatbotensilimabbalstilimabVerified on source pagesitcancer.org
- 1183PosterSafety and efficacy of the PD-1×VEGF bispecific antibody MK-2010 in an NSCLC cohort of the first-in-human MK-2010-001 studyCaicun ZhouMK-2010-001MK-2010Verified on source pagesitcancer.org
- 1186PosterSeven valent mKRAS lymph node targeted amphiphile vaccine drives mKRAS-specific T cell responses that correlate with improved clinical outcomes in the AMPLIFY-7P randomized phase 2 trialChristopher HaqqAMPLIFY-7PmKRAS lymph node targeted amphiphile vaccineVerified on source pagesitcancer.org
- 1190PosterSpatial and phenotypic characterization of tertiary lymphoid structures and immune organization in cutaneous squamous cell carcinoma using multiplex immunofluorescenceRachel Mattson (presented by Filippo Pullara)Verified on source pagesitcancer.org
- 1175OtherCombining PSMAxCD28 costimulatory T cell engager (TCE) JNJ-87189401 with pasritamig (KLK2xCD3): first-in-human phase 1 results of a dual-antigen targeted TCE regimen in prostate cancerLaura GrahamJNJ-87189401pasritamigVerified on source pagesitcancer.org
- 1177OtherPhase 1 evaluation of brenetafusp alone and in combination with tebentafusp in metastatic uveal melanomaAlexander Shoushtari (presented by Omid Hamid)brenetafusptebentafuspVerified on source pagesitcancer.org
- 1184OtherVGX-3100 DNA immunotherapy for HPV-16/18–associated cervical high-grade squamous intraepithelial lesions: a phase III randomized trialNenan Lyu (presented by Jeffrey Skolnik)VGX-3100Verified on source pagesitcancer.org
- 1185OtherIDP-023 allogeneic g-NK cells combined with isatuximab in relapse/refractory multiple myeloma: complete safety, efficacy, and tumor microenvironment remodeling from a Phase 1/2 First-in-Human studyKrina Patel (presented by Mark Frohlich)IDP-023isatuximabVerified on source pagesitcancer.org
- 1187OtherSafety and Efficacy of Cesalatamig, a Novel PD-1/VEGF Bispecific Antibody, as Monotherapy in PD-(L)1–Resistant/Refractory NSCLC: Results from Global, Multicenter, Open-Label Phase 1/2 Studies:Kai HeBiPAVE-001; BiPAVE-001 CNcesalatamigVerified on source pagesitcancer.org
- 1189OtherA Phase 1/1b study of the tumor-activated IL-2 prodrug WTX-124 alone or in combination with pembrolizumab in adults with relapsed/refractory, advanced/metastatic, immunotherapy-sensitive solid tumorsJustin MoserWTX-124pembrolizumabVerified on source pagesitcancer.org
- 605